BRPI0819909B8 - anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica - Google Patents
anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêuticaInfo
- Publication number
- BRPI0819909B8 BRPI0819909B8 BRPI0819909A BRPI0819909A BRPI0819909B8 BR PI0819909 B8 BRPI0819909 B8 BR PI0819909B8 BR PI0819909 A BRPI0819909 A BR PI0819909A BR PI0819909 A BRPI0819909 A BR PI0819909A BR PI0819909 B8 BRPI0819909 B8 BR PI0819909B8
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- functional fragment
- pharmaceutical composition
- isolated human
- synthetic antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US437807P | 2007-11-26 | 2007-11-26 | |
| US61/004,378 | 2007-11-26 | ||
| PCT/EP2008/009756 WO2009068204A1 (en) | 2007-11-26 | 2008-11-19 | Anti-mesothelin antibodies and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0819909A2 BRPI0819909A2 (pt) | 2017-12-19 |
| BRPI0819909B1 BRPI0819909B1 (pt) | 2021-04-20 |
| BRPI0819909B8 true BRPI0819909B8 (pt) | 2021-05-25 |
Family
ID=40351874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0819909A BRPI0819909B8 (pt) | 2007-11-26 | 2008-11-19 | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9023351B2 (enExample) |
| EP (3) | EP2215121B1 (enExample) |
| JP (3) | JP5608091B2 (enExample) |
| KR (1) | KR101559599B1 (enExample) |
| CN (2) | CN101952319B (enExample) |
| AU (1) | AU2008329221B2 (enExample) |
| BR (1) | BRPI0819909B8 (enExample) |
| CA (1) | CA2706529C (enExample) |
| CO (1) | CO6280409A2 (enExample) |
| CR (1) | CR11456A (enExample) |
| CU (1) | CU23833A3 (enExample) |
| CY (1) | CY1117437T1 (enExample) |
| DK (1) | DK2215121T3 (enExample) |
| DO (1) | DOP2010000150A (enExample) |
| EC (1) | ECSP10010191A (enExample) |
| ES (1) | ES2569513T3 (enExample) |
| GT (1) | GT201000148A (enExample) |
| HN (1) | HN2010001062A (enExample) |
| HR (1) | HRP20160485T1 (enExample) |
| HU (1) | HUE027358T2 (enExample) |
| IL (1) | IL205681A0 (enExample) |
| MA (1) | MA31862B1 (enExample) |
| MX (1) | MX2010005603A (enExample) |
| MY (1) | MY157164A (enExample) |
| NZ (1) | NZ585551A (enExample) |
| PL (1) | PL2215121T3 (enExample) |
| SI (1) | SI2215121T1 (enExample) |
| TN (1) | TN2010000234A1 (enExample) |
| UA (1) | UA106036C2 (enExample) |
| WO (1) | WO2009068204A1 (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ584633A (en) * | 2007-10-01 | 2011-11-25 | Bristol Myers Squibb Co | Human antibodies that bind mesothelin, and uses thereof |
| AU2008329221B2 (en) * | 2007-11-26 | 2013-11-07 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses therefor |
| AR076284A1 (es) * | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| PH12013501323A1 (en) * | 2010-12-20 | 2013-08-28 | Genentech Inc | Anti-mesothelin antibodies and immunoconjugates |
| EP3138581B1 (en) | 2011-03-17 | 2019-01-02 | The University of Birmingham | Re-directed immunotherapy |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| RU2610336C2 (ru) | 2011-04-21 | 2017-02-09 | Сиэтл Дженетикс, Инк. | Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение |
| US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9416190B2 (en) * | 2012-09-27 | 2016-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| PE20160996A1 (es) | 2013-12-23 | 2016-11-09 | Bayer Pharma AG | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp |
| US10392447B2 (en) | 2014-09-30 | 2019-08-27 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (DPRs) antibody |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| DK3298033T4 (da) | 2015-05-18 | 2023-10-02 | Tcr2 Therapeutics Inc | Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner |
| CN108025084B (zh) | 2015-06-22 | 2024-08-09 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物（adc）和抗体前药缀合物（apdc） |
| EP3316908A4 (en) * | 2015-06-30 | 2019-03-06 | Henlius Biotech Co., Ltd. | VASCULAR ENDOTHELIAL GROWTH FACTOR ANTI-RECEPTOR 2 (VEGFR2) ANTIBODY |
| BR112018003339A8 (pt) | 2015-08-21 | 2022-10-18 | Carsgen Therapeutics Ltd | Anticorpos antimesotelina completamente humanos e células imunoefetoras que direcionam mesotelina |
| KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EP4643874A2 (en) | 2015-12-22 | 2025-11-05 | Novartis AG | Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy |
| EP4219689A3 (en) | 2015-12-30 | 2023-12-20 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
| EP3418304B1 (en) * | 2016-02-15 | 2021-08-04 | Kanagawa Prefectural Hospital Organization | Recognition of membrane type mucin-like protein and clinical application thereof |
| KR20180118175A (ko) | 2016-03-04 | 2018-10-30 | 노파르티스 아게 | 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도 |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| CA3018630A1 (en) | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| KR20180134385A (ko) | 2016-04-15 | 2018-12-18 | 노파르티스 아게 | 선택적 단백질 발현을 위한 조성물 및 방법 |
| TW201806972A (zh) | 2016-05-27 | 2018-03-01 | 美商艾伯維生物醫療股份有限公司 | 雙特異性結合蛋白 |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| JP7085708B2 (ja) | 2016-06-20 | 2022-06-17 | エフ－スター セラピューティクス リミテッド | Ｌａｇ－３結合要素 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| MY191926A (en) | 2016-12-01 | 2022-07-18 | Regeneron Pharma | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| RU2761390C2 (ru) | 2016-12-21 | 2021-12-07 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы |
| JP7174704B2 (ja) | 2016-12-21 | 2022-11-17 | バイエル・アクチエンゲゼルシヤフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| WO2018232020A1 (en) | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| JP6339283B1 (ja) | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
| WO2019105835A1 (en) | 2017-11-29 | 2019-06-06 | Bayer Consumer Care Ag | Combinations of copanlisib and anetumab ravtansine |
| EP3728316B1 (en) | 2017-12-19 | 2025-02-26 | invoX Pharma Limited | Fc binding fragments comprising a pd-l1 antigen-binding site |
| EP3730612A4 (en) * | 2017-12-24 | 2021-09-01 | Noile-Immune Biotech, Inc. | IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE THAT SPECIFICALLY RECOGNIZES HUMAN MESOTHELIN, IL-7 AND CCL19 |
| MA52712A (fr) | 2018-04-27 | 2021-03-31 | Biogen Ma Inc | Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| US12344672B2 (en) | 2018-07-12 | 2025-07-01 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| EP3820898B1 (en) | 2018-07-12 | 2025-09-03 | invoX Pharma Limited | Antibody molecules that bind cd137 and ox40 |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| WO2020047501A1 (en) | 2018-08-30 | 2020-03-05 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN119896730A (zh) | 2018-12-17 | 2025-04-29 | 雷维托普有限公司 | 双免疫细胞衔接物 |
| JP2022514315A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021011040A (es) * | 2019-03-14 | 2021-12-10 | Morphosys Ag | Anticuerpos dirigidos contra c5ar. |
| JP7684947B2 (ja) | 2019-03-19 | 2025-05-28 | フンダシオ プリバダ インスティトゥト ディンベスティガシオ オンコロジカ デ バル エブロン | 癌の治療のための併用療法 |
| WO2020234114A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | A novel stable high concentration formulation for anetumab ravtansine |
| US20220267437A1 (en) * | 2019-07-29 | 2022-08-25 | Fred Hutchinson Cancer Research Center | Methods and compositions for inducing notch signaling in tumor microenvironments |
| CN119684459A (zh) | 2019-12-20 | 2025-03-25 | 安进公司 | 治疗实体瘤的靶向间皮素的cd40激动性多特异性抗体构建体 |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| WO2021252920A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン |
| CN116134027B (zh) | 2020-08-03 | 2025-01-24 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN116063527A (zh) * | 2021-09-30 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向间皮素的抗体及其用途 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| EP4581052A1 (en) | 2022-09-01 | 2025-07-09 | University of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
| CN120166937A (zh) | 2022-10-25 | 2025-06-17 | 佩普托米克公司 | 用于治疗癌症的联合疗法 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN116019939A (zh) * | 2022-11-24 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 靶向msln的分子探针以及用途 |
| EP4626930A2 (en) * | 2022-12-02 | 2025-10-08 | Jecho Laboratories, Inc. | Anti-mesothelin bispecific antibodies and methods of use |
| WO2024226827A2 (en) | 2023-04-25 | 2024-10-31 | Arsenal Biosciences, Inc. | Novel receptors for transcription regulation |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024251854A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with braf inhibitors for the treatment of cancer |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| CN121335714A (zh) | 2023-06-07 | 2026-01-13 | 瓦尔希伯伦私人肿瘤研究基金会 | 用于治疗癌症的与mek抑制剂的组合疗法 |
| CN117659133B (zh) * | 2023-12-06 | 2024-09-20 | 南京鼓楼医院 | 间皮素靶向结合蛋白、其编码核酸以及用途 |
| CN117843793B (zh) * | 2024-03-07 | 2024-07-09 | 深圳真实生物医药科技有限公司 | 抗间皮素抗体、抗原结合片段及其用途 |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| ES2212071T3 (es) | 1996-01-05 | 2004-07-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of | Antigeno de mesotelio y kits para marcarlo como diana. |
| DE69833459T2 (de) | 1997-12-01 | 2006-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| ATE328280T1 (de) * | 1999-02-26 | 2006-06-15 | Pacific Northwest Res Inst | Verfahren und zusammensetzungen zur karzinomdiagnose |
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
| US20090047211A1 (en) * | 2005-05-12 | 2009-02-19 | The Govt. Of The U.S. As Represented By The Sec. Of The Dept. Of Health And Human Services | Anti-mesothelin antibodies useful for immunological assays |
| RS53743B1 (sr) | 2005-05-18 | 2015-06-30 | Morphosys Ag | Anti-gm-csf antitela i njihova upotreba |
| EP1891113A2 (en) | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Antibodies directed to cd20 and uses thereof |
| NZ584633A (en) * | 2007-10-01 | 2011-11-25 | Bristol Myers Squibb Co | Human antibodies that bind mesothelin, and uses thereof |
| AU2008329221B2 (en) * | 2007-11-26 | 2013-11-07 | Bayer Intellectual Property Gmbh | Anti-mesothelin antibodies and uses therefor |
-
2008
- 2008-11-19 AU AU2008329221A patent/AU2008329221B2/en not_active Ceased
- 2008-11-19 HU HUE08855189A patent/HUE027358T2/en unknown
- 2008-11-19 EP EP08855189.0A patent/EP2215121B1/en active Active
- 2008-11-19 PL PL08855189T patent/PL2215121T3/pl unknown
- 2008-11-19 CA CA2706529A patent/CA2706529C/en active Active
- 2008-11-19 DK DK08855189.0T patent/DK2215121T3/en active
- 2008-11-19 CN CN200880125390.8A patent/CN101952319B/zh not_active Expired - Fee Related
- 2008-11-19 CN CN201410396441.8A patent/CN104151429B/zh not_active Expired - Fee Related
- 2008-11-19 NZ NZ585551A patent/NZ585551A/en not_active IP Right Cessation
- 2008-11-19 MX MX2010005603A patent/MX2010005603A/es active IP Right Grant
- 2008-11-19 EP EP16170412.7A patent/EP3103814A1/en not_active Withdrawn
- 2008-11-19 EP EP13168583.6A patent/EP2634196A1/en not_active Ceased
- 2008-11-19 KR KR1020107011375A patent/KR101559599B1/ko not_active Expired - Fee Related
- 2008-11-19 UA UAA201008006A patent/UA106036C2/uk unknown
- 2008-11-19 ES ES08855189.0T patent/ES2569513T3/es active Active
- 2008-11-19 HR HRP20160485TT patent/HRP20160485T1/hr unknown
- 2008-11-19 JP JP2010535269A patent/JP5608091B2/ja not_active Expired - Fee Related
- 2008-11-19 WO PCT/EP2008/009756 patent/WO2009068204A1/en not_active Ceased
- 2008-11-19 SI SI200831603A patent/SI2215121T1/sl unknown
- 2008-11-19 MY MYPI2010002379A patent/MY157164A/en unknown
- 2008-11-19 BR BRPI0819909A patent/BRPI0819909B8/pt not_active IP Right Cessation
- 2008-11-19 US US12/744,849 patent/US9023351B2/en active Active
-
2010
- 2010-05-11 IL IL205681A patent/IL205681A0/en active IP Right Grant
- 2010-05-20 GT GT201000148A patent/GT201000148A/es unknown
- 2010-05-20 DO DO2010000150A patent/DOP2010000150A/es unknown
- 2010-05-21 CO CO10061059A patent/CO6280409A2/es not_active Application Discontinuation
- 2010-05-21 CU CU2010000098A patent/CU23833A3/es active IP Right Grant
- 2010-05-21 HN HN2010001062A patent/HN2010001062A/es unknown
- 2010-05-21 EC EC2010010191A patent/ECSP10010191A/es unknown
- 2010-05-21 CR CR11456A patent/CR11456A/es unknown
- 2010-05-24 MA MA32865A patent/MA31862B1/fr unknown
- 2010-05-25 TN TN2010000234A patent/TN2010000234A1/fr unknown
-
2014
- 2014-07-03 JP JP2014137893A patent/JP2014221064A/ja active Pending
-
2015
- 2015-03-11 US US14/645,411 patent/US20150259433A1/en not_active Abandoned
-
2016
- 2016-04-27 CY CY20161100353T patent/CY1117437T1/el unknown
-
2018
- 2018-03-05 US US15/911,748 patent/US20180258181A1/en not_active Abandoned
- 2018-03-05 JP JP2018038254A patent/JP6717869B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0819909B8 (pt) | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica | |
| BR112022014667A2 (pt) | Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos | |
| BR112012013915A2 (pt) | anticorpos anti-c4. 4a e usos dos mesmos | |
| BR112021009275A2 (pt) | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. | |
| BR112019012040A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73. | |
| CY1125427T1 (el) | Anti-gm-csf αντισωματα και χρησεις αυτων | |
| BRPI0808940B8 (pt) | anticorpo humano-murino quimérico ou xegogeneico, humanizado, humano ou seu fragmento de ligação, vetor de expressão, microrganismo transgênico, método para preparar um anticorpo ou um fragmento de ligação, composição, composição de diagnóstico, uso do anticorpo ou fragmento de ligação, kit para o diagnóstico de um tumor e uso da molécula de antígeno ligante ao tumor | |
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| MX2024007719A (es) | Anticuerpos anti-pd-1 para el tratamiento de tumores. | |
| BRPI0618399A2 (pt) | região de ligação de antìgeno isolada que é especìfica para cd38, anticorpo isolado ou um fragmento funcional do mesmo que é especìfico para cd38, anticorpo isolado ou um fragmento funcional do mesmo, imunoglobulina isolada, cadeia pesada variável de uma região de ligação de antìgeno isolada, cadeia leve variável de uma região de ligação de antìgeno isolada, seqüência isolada de ácido nucléico, seqüência de ácido nucléico que codifica uma cadeia pesada variável de uma região de ligação de antìgeno isolada, seqüência de ácido nucléico, vetor, célula isolada, composição farmacêutica, uso da composição farmacêutica, método de indução de mortandade especìfica das células de tumor que expressam cd38, método de detecção da mortandade especìfica das células de tumor que expressam cd38, método de detecção da presença de cd38 em um tecido ou em célula de origem de miniporco, método de detecção de cd38 em um eritrócito que expressa cd38 e composição de diagnóstico | |
| PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
| BR112015029953A2 (pt) | anticorpos anti-tweakr e seus usos | |
| BR112018075737A2 (pt) | anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra. | |
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
| BR112015023262A2 (pt) | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR122020002402B8 (pt) | Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| BRPI0507489A (pt) | anticorpos humanos de anti-cd38 e para os seus usos | |
| BR112022012474A2 (pt) | Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes. | |
| BR112022017174A2 (pt) | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor | |
| BR112013009551A2 (pt) | anticorpos | |
| BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 | |
| BR112022013544A2 (pt) | Anticorpo monoclonal anti-lag3 e método de preparação do mesmo e uso do mesmo | |
| BR112021016791A2 (pt) | Proteínas de ligação de antígenos que se ligam a bcma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE) |
|
| B25A | Requested transfer of rights approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/11/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE) |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 17A ANUIDADE. |